Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib and Glucocorticoid in Polymyalgia Rheumatica (ITTG PMR)
NCT06172361Phase 3Completed
- Sponsor
- Zhejiang University
- Start
- Jan 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tofacitinib oral solution in polymyalgia rheumatica (PMR) (2 arms), sponsored by Zhejiang University. Primary endpoint: Proportion of patients with PMR-AS score <10 at 52 weeks. Started Jan 2024; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT06172361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172361.